Ehave Solutions Gain Traction in Cannabis Industry -- CFN Media

SEATTLE, WA, March 07, 2018 (GLOBE NEWSWIRE) -- CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering recent developments in the deployment of Ehave Inc.’s (OTCQB: EHVVF) Connect platform, an innovative bioinformatics tool that enables researchers, physicians, and patients to connect in a way that was never before possible. By bringing all of these parties together, everyone can work towards the common goal of improving patient outcomes on a highly personalized level.

The cannabis industry is expected to reach $50 billion by 2022 in the U.S. alone, according to Cowen & Co., driven by a growing number of states that have legalized the drug for medical and adult use. At the same time, a growing number of researchers have become interested in the drug as a potential treatment for a wide range of medical conditions. The problem is that it’s difficult to keep effective records in cannabis clinical trials.

Revive Therapeutics Collaboration

Ehave recently announced a collaboration agreement with Revive Therapeutics Ltd. to provide enhanced patient and clinical research data management. Under the terms of the agreement, Revive will integrate the Ehave Connect platform with its ongoing research involving the use of medical cannabis for the treatment of liver diseases, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and fibrosis.

“We are very excited with our collaboration with Ehave as it provides us with a foundation of employing next generation patient and clinical research data management solutions early on in the research and development phase of our liver disease program,” said Revive CEO Craig Leon. “Ehave’s platform will support our research and clinical decisions and it will allow us to make objective, data-driven decisions throughout the course of our research.”

The Ehave Connect platform collects and integrates patient data from clinical systems, licensed health surveys, and patient and clinician reported outcomes. By keeping patients engaged throughout the healthcare journey, the platform helps connect teams across disciplines and ensure that patients have the best treatments and options available to them.

“Our collaboration with Revive is an important step toward realizing Ehave’s broader goal of partnering with the healthcare community, and in particular, companies advancing novel medical cannabis products, to facilitate clinical trials and patient management with a single easy-to-use, end-to-end data informatics platform,” said Ehave CEO Prateek Dwivedi.

Aequus Pharma’s Clinical Trials

Ehave announced a collaboration with Aequus Pharmaceuticals Inc. just a week after its agreement with Revive. Under that agreement, Aequus will incorporate Ehave’s bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying cannabinoid-rich formulations for treating a number of neurological disorders.

“Our thinking regarding conducting clinical trials of various cannabinoid containing formulations has advanced substantially since we signed the original letter of intent with Ehave,” said Aequus CEO Doug Janzen. “We have a number of different clinical trials in late-stage planning and see multiple opportunities for us to leverage our traditional pharmaceutical expertise in designing and implementing clinical programs [in the cannabis space].”

The agreement involves Aequus paying Ehave a per-patient fee for trials conducted using its Ehave Connect platform. In return, Aequus will receive patient assessment, diagnostic, and therapeutic outcomes and side-effect profile content from formal and informal studies conducted using the platform. Aequus will also fully own all clinical results and data generated from trials using the Ehave Connect platform.

“Our robust bioinformatics platform allows us to provide customized, next generation clinical solutions that empower pharmaceutical developers such as Aequus to be successful,” said Ehave CEO Prateek Dwivedi. “We look forward to helping them advance their clinical programs and potentially improve outcomes for patients with neurological disorders who may benefit from Aequus’ products.”

Looking Ahead

Ehave Inc. (OTCQB: EHVVF) represents a compelling investment opportunity in the pharmaceutical and cannabis industries. With two new partnerships in March, the company has demonstrated its ability to execute its plan to become a leading platform for the research and development of cannabinoid therapeutics. Investors may want to take a closer look at the stock as it ramps up its commercialization with these new license agreements.

Please follow the link to read the full article:

For more information, visit the company’s website at

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

Disclaimer is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate., a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. received compensation for producing and presenting high quality and sophisticated content on along with financial and corporate news.  

The above article is sponsored content. Emerging Growth LLC, which owns and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation:


Contact Data